Skip to main content

Advertisement

SpringerLink
Log in

The prognostic value of CD133 expression in non-small cell lung cancer: a meta-analysis

  • Research Article
  • Published:
Tumor Biology

Abstract

CD133 has been identified as a potential cancer stem cell (CSC) marker in non-small cell lung cancer (NSCLC). However, the clinical and prognostic significance of CD133 in NSCLC remains controversial. In this study, a meta-analysis with a total number of 13 studies was performed to clarify the association between CD133 expression and clinical outcomes in publications up to June 2013. Odds ratios (ORs) and their 95 % confidence intervals (CIs) were used to assess the association between CD133 expression and the clinicopathological characteristics of NSCLC. Hazard ratios (HRs) and their 95 % CI were used to quantify the predictive ability of CD133 on NSCLC prognosis. Analysis of these data showed that CD133 expression was not associated with any clinicopathological parameters except for histology (pooled OR = 1.35, 95%CI = 1.04–1.76, P = 0.024) and tumor differentiation (pooled OR = 3.19, 95%CI = 1.10–9.21, P = 0.032). Simultaneously, we also found that positive CD133 expression was not associated with disease-free survival (DFS) (pooled HR = 1.76, 95 % CI = 0.87–3.57, P = 0.114, random-effect) but was associated with overall survival (OS) (pooled HR = 2.06, 95 % CI = 1.08–3.91, P = 0.027, random-effect). Overall, it is appropriate to regard CD133 expression as a potential prognostic factor for the OS of NSCLC patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.

    Article  PubMed  Google Scholar 

  2. Esposito L, Conti D, Ailavajhala R, Khalil N, Giordano A. Lung cancer: are we up to the challenge? Curr Genomics. 2010;11:513–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  3. Alberg AJ, Ford JG, Samet JM. Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132:29S–55.

    Article  CAS  PubMed  Google Scholar 

  4. Dontu G, Liu S, Wicha MS. Stem cells in mammary development and carcinogenesis: implications for prevention and treatment. Stem Cell Rev. 2005;1:207–13.

    Article  CAS  PubMed  Google Scholar 

  5. Ribatti D. Cancer stem cells and tumor angiogenesis. Cancer Lett. 2012;321:13–7.

    Article  CAS  PubMed  Google Scholar 

  6. Baccelli I, Trumpp A. The evolving concept of cancer and metastasis stem cells. J Cell Biol. 2012;198:281–93.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  7. Perona R, Lopez-Ayllon BD, de Castro Carpeno J, Belda-Iniesta C. A role for cancer stem cells in drug resistance and metastasis in non-small-cell lung cancer. Clin Transl Oncol. 2011;13:289–93.

    Article  CAS  PubMed  Google Scholar 

  8. Kitamura H, Okudela K, Yazawa T, Sato H, Shimoyamada H. Cancer stem cell: implications in cancer biology and therapy with special reference to lung cancer. Lung Cancer. 2009;66:275–81.

    Article  PubMed  Google Scholar 

  9. Salnikov AV, Gladkich J, Moldenhauer G, Volm M, Mattern J, Herr I. Cd133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients. Int J Cancer J Int Cancer. 2010;126:950–8.

    CAS  Google Scholar 

  10. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumour initiating cells. Nature. 2004;432:396–401.

    Article  CAS  PubMed  Google Scholar 

  11. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, et al. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007;445:111–5.

    Article  CAS  PubMed  Google Scholar 

  12. Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 2008;15:504–14.

    Article  CAS  PubMed  Google Scholar 

  13. Arne G, Kristiansson E, Nerman O, Kindblom LG, Ahlman H, Nilsson B, et al. Expression profiling of GIST: CD133 is associated with KIT exon 11 mutations, gastric location and poor prognosis. Int J Cancer J Int Cancer. 2011;129:1149–61.

    Article  CAS  Google Scholar 

  14. Boegl M, Prinz C. Cd133 expression in different stages of gastric adenocarcinoma. Br J Cancer. 2009;100:1365–6. author reply 1367.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  15. Wu S, Yu L, Wang D, Zhou L, Cheng Z, Chai D, et al. Aberrant expression of CD133 in non-small cell lung cancer and its relationship to vasculogenic mimicry. BMC Cancer. 2012;12:535.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. Woo T, Okudela K, Mitsui H, Yazawa T, Ogawa N, Tajiri M, et al. Prognostic value of CD133 expression in stage i lung adenocarcinomas. Int J Clin Exp Pathol. 2010;4:32–42.

    PubMed Central  PubMed  Google Scholar 

  17. Mizugaki H, Sakakibara-Konishi J, Kikuchi J, Moriya J, Hatanaka KC, Kikuchi E, Kinoshita I, Oizumi S, Dosaka-Akita H, Matsuno Y, Nishimura M. Cd133 expression: A potential prognostic marker for non-small cell lung cancers. Int J Clin Oncol. 2013.

  18. Sullivan JP, Spinola M, Dodge M, Raso MG, Behrens C, Gao B, et al. Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling. Cancer Res. 2010;70:9937–48.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  19. Yang X, Takano Y, Zheng HC. The pathobiological features of gastrointestinal cancers (review). Oncol Lett. 2012;3:961–9.

    PubMed Central  CAS  PubMed  Google Scholar 

  20. Liu L, Wu C, Wang Y, Zhong R, Duan S, Wei S, et al. Combined effect of genetic polymorphisms in p53, p73, and mdm2 on non-small cell lung cancer survival. J Thorac Oncol. 2011;6:1793–800.

    Article  PubMed  Google Scholar 

  21. Liu L, Yuan P, Wu C, Zhang X, Wang F, Guo H, et al. Assessment of XPD Lys751gln and XRCC1 t-77c polymorphisms in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy. Lung Cancer. 2011;73:110–5.

    Article  PubMed  Google Scholar 

  22. Chen S, Song X, Chen Z, Li X, Li M, Liu H, et al. CD133 expression and the prognosis of colorectal cancer: a systematic review and meta-analysis. PLoS One. 2013;8:e56380.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  23. Wen L, Chen XZ, Yang K, Chen ZX, Zhang B, Chen JP, et al. Prognostic value of cancer stem cell marker cd133 expression in gastric cancer: a systematic review. PLoS One. 2013;8:e59154.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  24. Liu YP, Yang CJ, Huang MS, Yeh CT, Wu AT, Lee YC, et al. Cisplatin selects for multidrug-resistant CD133+ cells in lung adenocarcinoma by activating notch signaling. Cancer Res. 2013;73:406–16.

    Article  CAS  PubMed  Google Scholar 

  25. Lundin A, Driscoll B. Lung cancer stem cells: Progress and prospects. Cancer Lett. 2012.

  26. Okudela K, Woo T, Mitsui H, Tajiri M, Masuda M, Ohashi K. Expression of the potential cancer stem cell markers, CD133, CD44, ALDH1, and beta-catenin, in primary lung adenocarcinoma-their prognostic significance. Pathol Int. 2012;62:792–801.

    Article  CAS  PubMed  Google Scholar 

  27. Xu YH, Zhang GB, Wang JM, Hu HC. B7-H3 and CD133 expression in non-small cell lung cancer and correlation with clinicopathologic factors and prognosis. Saudi Med J. 2010;31:980–6.

    PubMed  Google Scholar 

Download references

Acknowledgments

Research supported by National Natural Science Foundation of China (#81370078, #30930080, #81161120537, and #81001231), malignant tumor biomarkers in Jiangsu Province Key Laboratory (#11ZLKF09), the Natural Science Foundation of Jiangsu Province (#BK2012840), the Postdoctoral Science Foundation of China (#20100481165), Undergraduates Practice and InnovationTraining Project of Jiangsu Higher Education Institutes (#2012JSSPITP1021), and the Priority Academic Program Development of Jiangsu Higher Education Institutions (Public Health and Preventive Medicine).

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Department of Oncology, Yixing People’s Hospital, 75 Zhenguan Road, Yixing, 214200, Jiangsu Province, People’s Republic of China

    Weimin Wang, Jianliang Deng, Jianping Zhou & Yan Zhou

  2. Department of Molecular Cell Biology and Toxicology, Jiangsu Key Lab of Cancer Biomarkers, Prevention & Treatment, Cancer Center; School of Public Health, Nanjing Medical University, 140 Hanzhong Road, Nanjing, 210029, People’s Republic of China

    Yansu Chen, Shouyu Wang & Jianwei Zhou

Authors
  1. Weimin Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yansu Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jianliang Deng
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jianping Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yan Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shouyu Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jianwei Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Yan Zhou or Shouyu Wang.

Additional information

Weimin Wang, Yansu Chen, and Jianliang Deng contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, W., Chen, Y., Deng, J. et al. The prognostic value of CD133 expression in non-small cell lung cancer: a meta-analysis. Tumor Biol. 35, 9769–9775 (2014). https://doi.org/10.1007/s13277-014-2270-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-014-2270-9

Keywords

Search

Navigation